Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ursodeoxycholic acid to attenuate statin-induced impaired glucose tolerance
ChiCTR2400091742Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in hypercholesterolemia and prediabetes comparing Ursodeoxycholic acid arm with Placebo arm (2 arms). Primary endpoint: Glycosylated hemoglobin (HbA1c) at day 180. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
ursodeoxycholic acid
03
Conditions
hypercholesterolemiaprediabetes
Beyond the preview
Go deeper on ChiCTR2400091742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091742.